Prognostic role of tumour-infiltrating inflammatory cells in brain tumours: Literature review

Current Opinion in Neurology

Volumn 28, Issue 6, 2015, Pages 647-658

  Bieńkowski, Michał ^a,b   Preusser, Matthias ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Brain tumours; Immune infiltrates; Prognosis; Tumour associated macrophages; Tumour infiltrating lymphocytes

Indexed keywords

BRAIN METASTASIS; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE COURSE; GLIOMA; INFLAMMATORY INFILTRATE; INFORMATION RETRIEVAL; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MENINGIOMA; MICROGLIA; NATURAL KILLER CELL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; BRAIN NEOPLASMS; HUMAN; IMMUNOLOGY;

TUMOR MARKER;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; PROGNOSIS;

EID: 84947493002     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000251     Document Type: Review

References (111)

1. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-384.
2. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmall-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16:257-265.
3. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New Engl J Med 2015; 372:311-319.
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545.
5. Galon J, Pages F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10:205.
6. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the "Immunoscore" in the classification of malignant tumours. J Pathol 2014; 232:199-209.
7. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66:605-612.
8. Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25:261-267.
9. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-1964.
10. Gooden MJM, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with metaanalysis. Br J Cancer 2011; 105:93-103.
11. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med 2004; 10:942-949.
12. Yu P, Fu Y-X. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 2006; 86:231-245.
13. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66:605-612.
14. Glass R, Synowitz M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol 2014; 128:347-362.
15. Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res 2014; 20:5620-5629.
16. Louis D, Ohgaki H, Wiestler O, Cavenee W. World Health Organization classification of tumours of the central nervous system. IARC, Lyon 2007; pp. 25-68, 164-172, 188-192, 247-252.
17. Soffietti R, Baumert B, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO∗ Task Force. Eur J Neurol 2010; 17:1124-1133.
18. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 352:987-996.
19. Rossi ML, Hughes JT, Esiri MM, et al. Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol 1987; 74:269-277.
20. Stevens A, Kloter I, Roggendorf W. Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 1988; 61:738-743.
21. Shinonaga M, Chang CC, Suzuki N, et al. Immunohistological evaluation of macrophage infiltrates in brain tumors. Correlation with peritumoral edema. J Neurosurg 1988; 68:259-265.
22. Hitchcock ER, Morris CS. Mononuclear cell infiltration in central portions of human astrocytomas. J Neurosurg 1988; 68:432-437.
23. Kuppner MC, Hamou MF, de Tribolet N. Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res 1988; 48:6926-6932.
24. Rossi ML, Jones NR, Candy E, et al. The mononuclear cell infiltrate compared with survival in high-grade astrocytomas. Acta Neuropathol 1989; 78:189-193.
25. Vaquero J, Coca S, Oya S, et al. Presence and significance of NK cells in glioblastomas. J Neurosurg 1989; 70:728-731.
26. Morimura T, Neuchrist C, Kitz K, et al. Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation. Acta Neuropathol 1990; 80:287-294.
27. Rossi ML, Buller J, Heath SA, Coakham HB. Monocyte/macrophage infiltrate in 41 oligodendrogliomas. Paraffin-wax study. Pathol Res Pract 1991; 187:166-169.
28. Rossi ML, Esiri MM, Jones NR, et al. Characterization of the mononuclear cell infiltrate and HLA-Dr expression in 19 oligodendrogliomas. Surg Neurol 1991; 36:119-125.
29. Zurita M, Vaquero J, Coca S, et al. Tumor-infiltrating lymphocytes expressing IOT-10 marker. An immunohistochemical study of a series of 185 brain tumors. Histol Histopathol 1993; 8:345-350.
30. Yamanaka R, Tanaka R, Saito T. Immunohistochemical analysis of tumor-infiltrating lymphocytes and adhesion molecules (ICAM-1, NCAM) in human gliomas. Neurol Med Chir (Tokyo) 1994; 34:583-587.
31. Strik HM, Stoll M, Meyermann R. Immune cell infiltration of intrinsic and metastatic intracranial tumours. Anticancer Res 2004; 24:37-42.
32. Roggendorf W, Strupp S, Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 1996; 92:288-293.
33. Giometto B, Bozza F, Faresin F, et al. Immune infiltrates and cytokines in gliomas. Acta Neurochir (Wien) 1996; 138:50-56.
34. Leung SY, Wong MP, Chung LP, et al. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 1997; 93:518-527.
35. Nishie A, Ono M, Shono T, et al. Macrophage infiltration and heme oxyge-nase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 1999; 5:1107-1113.
36. Deininger MH, Pater S, Strik H, Meyermann R. Macrophage/microglial cell subpopulations in glioblastoma multiforme relapses are differentially altered by radiochemotherapy. J Neurooncol 2001; 55:141-147.
37. Preusser M, Ströbel T, Birner P, et al. Presence of D110 antigen expressing immunocompetent cells in glioblastoma associates with prolonged survival. Neuropathol Appl Neurobiol 2004; 30:608-614.
38. Avninder S, Sharma MC, Deb P, et al. Gemistocytic astrocytomas: histo-morphology, proliferative potential and genetic alterations-a study of 32 cases. J Neurooncol 2006; 78:123-127.
39. Nakabayashi H, Nakashima M, Hara M, et al. Clinico-pathological significance of RCAS1 expression in gliomas: a potential mechanism of tumor immune escape. Cancer Lett 2007; 246:182-189.
40. Mittelbronn M, Simon P, Löffler C, et al. Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J Neuroimmunol 2007; 189:50-58.
41. Waziri A, Killory B, Ogden AT, et al. Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol 2008; 180:7673-7680.
42. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008; 14:5166-5172.
43. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216:15-24.
44. Okada M, Saio M, Kito Y, et al. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int J Oncol 2009; 34:1621-1627.
45. Strojnik T, Kavalar R, Zajc I, et al. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res 2009; 29:3269-3279.
46. Barcia C, Gómez A, Gallego-Sanchez JM, et al. Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. Am J Pathol 2009; 175:786-798.
47. Jacobs JFM, Idema AJ, Bol KF, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 2009; 11:394-402.
48. Jacobs JF, Idema AJ, Bol KF, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010; 225:195-199.
49. Kren L, Muckova K, Lzicarova E, et al. Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity? J Neu-roimmunol 2010; 220:131-135.
50. Yang I, Tihan T, Han SJ, et al. CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 2010; 17:1381-1385.
51. Lohr J, Ratliff T, Huppertz A, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-b. Clin Cancer Res 2011; 17:4296-4308.
52. Yang I, Han SJ, Sughrue ME, et al. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J Neurosurg 2011; 115:505-511.
53. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17:1603-1615.
54. Kim Y-H, Jung T-Y, Jung S, et al. Tumour-infiltrating T-cell subpopulations in glioblastomas. Br J Neurosurg 2012; 26:21-27.
55. Engler JR, Robinson AE, Smirnov I, et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One 2012; 7:e43339.
56. Donson AM, Birks DK, Schittone SA, et al. Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors. J Immunol 2012; 189:1920-1927.
57. Komohara Y, Horlad H, Ohnishi K, et al. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci 2012; 103:2165-2172.
58. Yeung JT, Hamilton RL, Ohnishi K, et al. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblas-toma. Clin Cancer Res 2013; 19:1816-1826.
59. Prosniak M, Harshyne LA, Andrews DW, et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res 2013; 19:3776-3786.
60. Hewedi IH, Radwan NA, Shash LS, Elserry TH. Perspectives on the im-munologic microenvironment of astrocytomas. Cancer Manag Res 2013; 5:293-299.
61. Lu-Emerson C, Snuderl M, Kirkpatrick ND, et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol 2013; 15:1079-1087.
62. Kmiecik J, Poli A, Brons NHC, et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at thesystemic level. J Neuroimmunol 2013; 264:71-83.
63. Yue Q, Zhang X, Ye H, et al. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol 2014; 116:251-259.
64. Han S, Zhang C, Li Q, et al. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer 2014; 110:2560-2568.
65. Zeiner PS, Preusse C, Blank A-E, et al. MIF receptor CD74 is restricted to microglia/macrophages, associated with a M1-polarized immune milieu and prolonged patient survival in gliomas. Brain Pathol 2014; 25:491-504.
66. Ding P, Wang W, Wang J, et al. Expression oftumor-associated macrophage in progression of human glioma. Cell Biochem Biophys 2014; 70:1625-1631.
67. Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 2014; 17:1064-1075.
68. Sayour EJ, McLendon P, McLendon R, et al. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 2015; 64:419-427.
69. Lapa C, Linsenmann T, Lückerath K, et al. Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy? PLoS One 2015; 10:e0122269.
70. Rutledge WC, Kong J, Gao J, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res 2013; 19:4951-4960.
71. Abou-Ghazal M, Yang DS, Qiao W, et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 2008; 14:8228-8235.
72. Cooper LAD, Gutman DA, Chisolm C, et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 2012; 180:2108-2119.
73. Bashir R, Chamberlain M, Ruby E, Hochberg FH. T-cell infiltration of primary CNS lymphoma. Neurology 1996; 46:440-444.
74. Riemersma SA, Oudejans JJ, Vonk MJ, et al. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol 2005; 206:328-336.
75. Ponzoni M, Berger F, Chassagne-Clement C, et al. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol 2007; 138:316-323.
76. Kumari N, Krishnani N, Rawat A, et al. Primary central nervous system lymphoma: prognostication as per international extranodal lymphoma study group score and reactive CD3 collar. J Postgraduate Med 2009; 55:247.
77. Preusser M, Woehrer A, Koperek O, et al. Primary central nervous system lymphoma: a clinicopathological study of 75 cases. Pathology 2010; 42:547-552.
78. Venetz D, Ponzoni M, Schiraldi M, et al. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. Int J Cancer 2010; 127:2300-2312.
79. Komohara Y, Horlad H, Ohnishi K, et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop 2011; 51:93-99.
80. Berghoff AS, Ricken G, Widhalm G, et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol 2014; 33:42-49.
81. Yano S, Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg 2006; 105:538-543.
82. Vranic A, Peyre M, Kalamarides M. New insights into meningioma: from genetics to trials. Curr Opin Oncol 2012; 24:660-665.
83. Preusser M, Marosi C. Antiangiogenic treatment of meningiomas. Curr Treat Options Neurol 2015; 17:359.
84. Mawrin C, Chung C, Preusser M. Biology and clinical management challenges in meningioma. Am Soc Clin Oncol Educ Book 2015; 35:e106-e115.
85. Rossi ML, Cruz Sanchez F, Hughes JT, et al. Immunocytochemical study of the cellular immune response in meningiomas. J Clin Pathol 1988; 41:314-319.
86. Becker I, Roggendorf W. Immunohistological investigation of mononuclear cell infiltrates in meningiomas. Acta Neuropathol 1989; 79:211-216.
87. Vaquero J, Coca S, Pontón P, et al. Natural killer cells in meningiomas. Histol Histopathol 1991; 6:369-372.
88. Bø L, Mørk S, Nyland H. An immunohistochemical study of mononuclear cells in meningiomas. Neuropath Appl Neurobiol 1992; 18:548-558.
89. Roessler K, Dietrich W, Kitz K. Expression of BCL-2 oncoprotein on tumor cells and tumor-infiltrating lymphocytes (TIL) in meningiomas. Neurosurg Rev 1999; 22:205-209.
90. Mosnier JF, Perret AG, Scoazec JY, Brunon J. Expression of beta2 integrins and macrophage-associated antigens in meningeal tumours. Virchows Arch 2000; 436:131-137.
91. Grund S, Schittenhelm J, Roser F, et al. The microglial/macrophagic response at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol 2009; 35:82-88.
92. Domingues PH, Teodósio C, Ortiz J, et al. Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in me-ningiomas. Am J Pathol 2012; 181:1749-1761.
93. Domingues PH, Teodósio C, Otero A, et al. Association between inflammatory infiltrates and isolated monosomy 22/del(22q) in meningiomas. PLoS One 2013; 8:e74798.
94. Fang L, Lowther DE, Meizlish ML, et al. The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol 2013; 15:1479-1490.
95. Du Z, Abedalthagafi M, Aizer AA, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 2015; 6:4704-4716.
96. Ding Y, Qiu L, Xu Q, et al. Relationships between tumor microenvironment and clinicopathological parameters in meningioma. Int J Clin Exp Pathol 2014; 7:6973-6979.
97. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiol-ogy. J Neurooncol 2005; 75:5-14.
98. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1, 960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70:510-514.
99. Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:17-32.
100. Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:33-43.
101. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radio-surgery in the management of patients with newly diagnosed brain metas-tases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:45-68.
102. Mehta MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:71-83.
103. Berghoff AS, Bartsch R, Wöhrer A, et al. Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathol 2014; 128:879-891.
104. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13:459-465.
105. Vaquero J, Coca S, Escandón J, et al. Immunohistochemical study of IOT-10 natural killer cells in brain metastases. Acta Neurochir (Wien) 1990; 104:17-20.
106. He BP, Wang JJ, Zhang X, et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol Med 2006; 12:161-170.
107. Pukrop T, Dehghani F, Chuang H-N, et al. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 2010; 58:1477-1489.
108. Berghoff AS, Lassmann H, Preusser M, Höftberger R. Characterization of the inflammatory response to solid cancer metastases in the human brain. Clin Exp Metastasis 2013; 30:69-81.
109. Amit M, Laider-Trejo L, Shalom V, et al. Characterization of the melanoma brain metastatic niche in mice and humans. Cancer Med 2013; 2:155-163.
110. Berghoff AS, Ricken G, Widhalm G, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 2015; 66:289-299.
111. Berghoff A, Fuchs E, Ricken G, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 2015. (In press).